A new report from the US non-profit Physicians for Human Rights (PHR) has issued a stark warning for the healthcare industry. Recent HIV Funding Cuts from the Trump administration are directly threatening South Africa’s ability to deploy lenacapavir. This twice-yearly injectable has been celebrated as a major breakthrough in HIV prevention.
HIV Funding Cuts Threaten Life-Saving Healthcare Infrastructure
The PHR report argues that the withdrawal of US financial support has crippled the systems necessary for drug distribution.
Historically, the US has provided extensive support through the President’s Emergency Plan for AIDS Relief (PEPFAR). However, executive orders signed in January 2025 have severely reduced this aid. While the South African government funds the majority of its own response, US support was vital for specialised delivery platforms.
The report drew on interviews with 40 healthcare professionals, researchers, and patients. It concluded that the current policy shift has wasted hundreds of millions of dollars in previous investments. By abandoning prevention technologies like lenacapavir, the administration is dismantling decades of collaborative work.
The Potential of Lenacapavir Amidst Budgetary Shortfalls
Lenacapavir is considered a "game-changer" because it provides almost complete protection against infection. Clinical trials in 2024 demonstrated its efficacy, particularly for women. South Africa played a pivotal role in these trials. The nation received its first shipment of 37,920 doses earlier this month.
Despite this arrival, the Health Department has yet to announce a launch date. Experts warn that the medicine alone is not enough. Francois Venter, executive director of the Ezintsha research institute, said that for lenacapavir to work, you need a delivery platform. He notes that the systems required to administer these injections have been almost completely dismantled following the US withdrawal.
How HIV Funding Cuts Undermine Decades of Global Progress
The impact of these HIV Funding Cuts extends beyond simple balance sheets. Thomas McHale, director of public health at PHR, describes the "America First" approach as a threat to global health security. He argues that shuttering world-class research and life-saving programmes harms both South Africans and the global public.
The specialised programmes designed for earlier prevention drugs, such as cabotegravir, have already begun to collapse. This infrastructure was meant to serve as the foundation for the lenacapavir rollout. Without it, the logistical challenge of reaching millions of at-risk individuals becomes nearly insurmountable.
Navigating the Future of South Africa's HIV Response
The South African government is currently attempting to bridge the gap. It plans to fund the initial phase of the rollout using grants from the Global Fund to Fight AIDS, TB, and Malaria. However, this is viewed as a temporary measure rather than a long-term solution.
Industry leaders remain concerned that the lack of a stable delivery system will lead to a "colossal waste of resources." While the first batch of lenacapavir is physically in the country, the human and technical resources to distribute it are rapidly vanishing. The healthcare sector now faces the challenge of rebuilding these platforms under extreme financial pressure.
Read the Original Article (May require a subscription)
Tags